Expects to Begin Processing New Blood and Toxicology Samples in June
Exploring Additional Lab Opportunities in Florida, Georgia, Texas, Pennsylvania, California, and the Northwest U.S.
MILTON, GA, May 21, 2018 (GLOBE NEWSWIRE) -- Attis Industries, Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), an integrated technology and innovations holding company, today announced that it is nearing completion of a new blood and toxicology laboratory in Tulsa, Oklahoma. Attis will operate the 1,800 square foot laboratory, which will be dedicated to running samples reimbursed by Medicare or individual state Medicaid programs only (“federal lab”). It is anticipated that the lab will begin processing samples in June and be at full capacity for both blood and toxicology specimens by mid-September.
Attis currently offers commercial laboratory services for an extensive list of physician clients through multiple hospital laboratory facilities located in the Midwest. This new facility will be the first federal lab managed by Attis. “We have a large customer base of physician offices who prefer our lab services but want to use one company for all of their laboratory needs. By processing both Medicare and Medicaid samples in this location, we will now provide a comprehensive solution for those customers,” stated Jeff Cosman, Chief Executive Officer of Attis Industries.
Attis’ laboratory will provide a phlebotomist onsite so that local doctors can send patients directly to the lab for blood draws. They also plan to offer low volume blood tubes which can significantly reduce the amount of blood that must be collected, without compromising lab results, for pediatric patients and those requiring frequent blood draws. “These offerings enable us to enhance the experience for both the patient and the physician. We are continually looking for ways to add value for our customers, and we continue to explore other laboratory possibilities in Florida, Georgia, Texas, Pennsylvania, California, and the Northwest U.S.” said Cosman.
The laboratory has already received COLA accreditation for laboratory quality assurance, expects CLIA certification in the coming weeks, and is now in the application process for Medicare coverage for all states and Medicaid coverage in Oklahoma, Arkansas, Missouri, Texas, Colorado and New Mexico. The laboratory will be located at 3336 E 51st Street in Tulsa, Oklahoma.
Attis Industries, Inc.
Attis Industries, Inc. (NASDAQ: ATIS) is a holding company defined by our commitment to servicing our customers with unwavering respect, fairness and care. We are focused on finding and implementing solutions for the resource needs and challenges of our customers with a fundamental objective to seek rewarding solutions through technology and innovation. Our healthcare business centers on creating community-based synergies through collaborations and software solutions. Our innovation business strives to create value from recovered resources. For more information, visit: www.attisind.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to continue to meet the listing requirements of NASDAQ; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company’s go-forward business, and the risks identified and discussed under the caption “Risk Factors” in the Attis Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2018 and the other documents Attis files with the SEC from time to time. There will be events in the future, however, that Attis is not able to predict accurately or control. Attis’s actual results may differ materially from the expectations that Attis describes in its forward-looking statements. Factors or events that could cause Attis’s actual results to materially differ may emerge from time to time, and it is not possible for Attis to accurately predict all of them. Any forward-looking statement made by Attis in this press release speaks only as of the date on which Attis makes it. Attis undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.